BridgeMD
Beta-Blockers in Takotsubo Syndrome: A Randomized Clinical Trial
EU CTIS ID: 2023-510213-25-01
What this study is testing
To evaluate the clinical efficacy of the most widely used pharmacological therapeutic strategy in patients with Takotsubo Syndrome (TT) in clinical practice. Namely, to assess the role of beta-blockers with alpha activity or nitric oxide liberation, to facilitate left ventricular function recovery on echocardiography in TT patients. The consistency of the treatment effect will be examined among several predefined relevant clinical subgroups after adjusting for multiple comparisons.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Written informed consent. • Diagnosis of TT (+) with exclusion of significant culprit coronary artery disease by invasive angiography (++)
You likely can't join if
- • Patients diagnosed of TT > 48 hours before. • Persistent cardiogenic shock or severe hemodynamic instability • Persistent severe (>30 mmHg) intraventricular gradient • Previous diagnosis of severe valvular or ventricular disease or prior myocardial infarction secondary to atherosclerotic CAD • Patients already receiving treatment with beta-blockers (*) • Absolute contraindication/indication for beta-blockers (**) • Poor echocardiographic window • Pregnant or breastfeeding women. • Participation in another clinical trial.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.